Detailed price information for Medicenna Therapeutics Corp (MDNA-T) from The Globe and Mail including charting and trades.
ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results